PMID: 16529548Mar 15, 2006Paper

Treatment of acute leukaemias with monoclonal antibodies: current status and future prospects

Cardiovascular & Hematological Agents in Medicinal Chemistry
G LeoneL Pagano

Abstract

Monoclonal antibodies are a new class of agents targeted at specific receptors on cancer cells. In addition to direct cellular effects, antibodies can carry substances to the targeted cells, such as radioactive isotopes, toxins, and antineoplastic agents. At present monoclonal antibodies, directed against both lymphoid antigens (CD 20 and CD 52) and a myeloid antigen (CD33) are available for clinical use. In ALL, rituximab, a humanized anti CD20 antibody, has been combined to chemotherapy mainly in mature B-ALL and Burkitt's lymphoma and preliminary results are promising. Alemtuzumab is an anti-CD52 humanized antibody, which showed anti-tumour activity in CLL; clinical effects were observed in some patients with relapsed adult ALL. Monoclonal antibodies against myeloid antigens have been prevalently used in acute myeloid leukaemias (AML), where the most utilised immunological target is CD33. The CD33 molecule is expressed by approximately 90% of AMLs but not on CD34(+) bone marrow-resident hematopoietic stem cells. The humanized anti-CD33 monoclonal antibody HuM195 has only modest activity against overt AML, but it can eliminate minimal residual disease. Radioimmunotherapy with beta-particle-emitting isotopes targeting CD33 sho...Continue Reading

Citations

Feb 9, 2012·Clinical and Experimental Medicine·Dongfeng ZengPeiyan Kong
Jun 15, 2007·Journal of Biotechnology·Ana M AzevedoM Raquel Aires-Barros
May 21, 2013·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Claudia FriesenErich Miltner
Mar 17, 2007·Cytometry. Part a : the Journal of the International Society for Analytical Cytology·Amir H Iranpour FeridaniBo Baldetorp
Jul 11, 2006·Current Opinion in Allergy and Clinical Immunology·Mariana Castells
Aug 20, 2019·Immunotherapy·Faezeh GhaemdoustNima Rezaei
Jul 17, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Lei WuJ Blake Bartlett
Jun 15, 2007·Journal of Chromatography. a·P A J RosaM R Aires-Barros

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Related Papers

Current Protein & Peptide Science
M S Nayeem, Rizwan H Khan
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
Jorge BenavidesMarco Rito-Palomares
© 2021 Meta ULC. All rights reserved